| Autor: |
Holtzman, Noa G., Lebowitz, Michael S., Koka, Rima, Baer, Maria R., Malhotra, Kanam, Shahlaee, Amir, Ghanbari, Hossein A., Bentzen, Søren M., Emadi, Ashkan |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology; 12/22/2021, Vol. 11, p1-8, 8p |
| Abstrakt: |
Background: Aspartate β-hydroxylase (ASPH) is an embryonic transmembrane protein aberrantly upregulated in cancer cells, associated with malignant transformation and, in some reports, with poor clinical prognosis. Objective: To report the expression patterns of ASPH in acute myeloid leukemia (AML). Methods: Cell surface expression of ASPH was measured via 8-color multiparameter flow cytometry in 41 AML patient samples (31 bone marrow, 10 blood) using fluorescein isothiocyanate (FITC)-conjugated anti-ASPH antibody, SNS-622. A mean fluorescent intensity (MFI) of 10 was used as a cutoff for ASPH surface expression positivity. Data regarding patient and disease characteristics were collected. Results: ASPH surface expression was found on AML blasts in 16 samples (39%). Higher ASPH expression was seen in myeloblasts of African American patients (p=0.02), but no correlation was found between ASPH expression and other patient or disease characteristics. No association was found between ASPH status and CR rate (p=0.53), EFS (p=0.87), or OS (p=0.17). Conclusions: ASPH is expressed on blasts in approximately 40% of AML cases, and may serve as a new therapeutically targetable leukemia-associated antigen. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
